Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis - 07/01/16
, María Jara-Acevedo, MSc b, c, José Mário Morgado, MSc a, b, Andrés García-Montero, PhD b, c, Laura Sánchez-Muñoz, MD, PhD a, b, Cristina Teodósio, PhD b, c, Almudena Matito, MD, PhD a, b, Andrea Mayado, PhD b, c, Carolina Caldas, MSc b, c, Manuela Mollejo, MD, PhD b, d, Alberto Orfao, MD, PhD b, c, ∗, Luis Escribano, MD, PhD b, ∗Abstract |
Background |
Well-differentiated systemic mastocytosis (WDSM) is a rare variant of systemic mastocytosis (SM) characterized by bone marrow (BM) infiltration by mature-appearing mast cells (MCs) often lacking exon 17 KIT mutations. Because of its rarity, the clinical and biological features of WDSM remain poorly defined.
Objective |
We sought to determine the clinical, biological, and molecular features of a cohort of 33 patients with mastocytosis in the skin in association with BM infiltration by well-differentiated MCs and to establish potential diagnostic criteria for WDSM.
Methods |
Thirty-three patients with mastocytosis in the skin plus BM aggregates of round, fully granulated MCs lacking strong CD25 and CD2 expression in association with clonal MC features were studied.
Results |
Our cohort of patients showed female predominance (female/male ratio, 4:1) and childhood onset of the disease (91%) with frequent familial aggregation (39%). Skin involvement was heterogeneous, including maculopapular (82%), nodular (6%), and diffuse cutaneous (12%) mastocytosis. KIT mutations were detected in only 10 (30%) of 33 patients, including the KIT D816V (n = 5), K509I (n = 3), N819Y (n = 1), and I817V (n = 1) mutations. BM MCs displayed a unique immunophenotypic pattern consisting of increased light scatter features, overexpression of cytoplasmic carboxypeptidase, and aberrant expression of CD30, together with absent (79%) or low (21%) positivity for CD25, CD2, or both. Despite only 9 (27%) of 33 patients fulfilling the World Health Organization criteria for SM, our findings allowed us to establish the systemic nature of the disease, which fit with the definition of WDSM.
Conclusions |
WDSM represents a rare clinically and molecularly heterogeneous variant of SM that requires unique diagnostic criteria to avoid a misdiagnosis of cutaneous mastocytosis per current World Health Organization criteria.
Le texte complet de cet article est disponible en PDF.Key words : Mast cell, mastocytosis, well differentiated, KIT, imatinib
Abbreviations used : ASM, BM, CM, CPA, DCM, FACS, FSC, GIST, HUMARA, ISM, MC, MCL, MIS, MPCM, NM, SM, SM-AHNMD, SSC, SSM, sT, TKI, WDSM, WHO, XCIP
Plan
| Supported by grants from Asociación Española de Mastocitosis, Madrid, Spain (grant AEDM 2014); Instituto de Salud Carlos III, FEDER, Ministry of Economy and Competitivity, Madrid, Spain (grant PI11/02399); Fundación Ramón Areces, Madrid, Spain (grant CIVP16A1806); and Novartis Farmacéutica, S.A., Spain. |
|
| Disclosure of potential conflict of interest: I. Álvarez-Twose has received research support from Novartis Farmacéutica, S.A., Spain. A. García-Montero has received research support from Fundacion Ramon Areces (grant no. CIVP16A1806) and ISCIII Ministerio de Economia y Competitividad (grant no. PI11/02399). A. Orfao has received research support from Fundacion Ramon Areces (grant no. CIVP16A1806). The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 137 - N° 1
P. 168 - janvier 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
